BridgeBio Pharma gains after H.C. Wainwright raises PT
09/06/2025 19:17
** Shares of drugmaker BridgeBio Pharma BBIO.O rise 2.7% to $39.67 ** Brokerage H.C. Wainwright raises PT to $56 from $53 ** Believe BBIO's rare heart disease drug, acoramidis, could reach annualized revenue run rate of more than $1 billion in mid- to late 2027 in the U.S. — H.C. Wainwright ** Acoramidis reduced incidence of atrial fibrillation events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), BBIO said in May ** Believe that this evidence, coupled with the growing proof that increased TTR stabilization extent is closely linked to favorable outcomes, should accelerate acoramidis market adoption — brokerage ** BBIO has fallen 8.3% YTD, as of last close (Reporting by Juby Babu in Mexico City) ((Juby.Babu@thomsonreuters.com))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels